Quarterly ResultAug 10, 2026, 04:12 PM
Fractyl Health Q2 Net Loss $25.5M; Revita shows durable weight maintenance
AI Summary
Fractyl Health reported a Q2 2026 net loss of $25.5 million, an improvement from $27.9 million in Q2 2025, driven by reduced R&D expenses. The company announced positive one-year data from its Revita REMAIN-1 Midpoint Cohort, showing patients maintained up to 84% of prior GLP-1-induced weight loss, and REVEAL-1 Cohort data showing 78% maintenance. Fractyl reiterated its cash runway into early 2027 and confirmed REMAIN-1 Pivotal Cohort topline data is on track for early Q4 2026, with a potential FDA De Novo submission later in Q4 2026.
Key Highlights
- Q2 2026 Net Loss: $(25.5) million, improved from $(27.9) million YoY.
- Q2 2026 R&D Expenses: $13.8 million, a $7.3 million decrease YoY.
- Cash and cash equivalents: $47.1 million as of June 30, 2026.
- Cash runway guidance: Extends into early 2027.
- REMAIN-1 Midpoint Cohort: Revita patients maintained 84% of GLP-1 weight loss.
- REVEAL-1 Cohort: Patients maintained 78% of GLP-1 weight loss after Revita.
- REMAIN-1 Pivotal Cohort topline data: Expected early Q4 2026.
- Potential FDA De Novo submission: Targeted for late Q4 2026.
Price Impact
More from GUTS